EXCLUSIVE LICENSE AGREEMENT by and between INNOVATION PHARMACEUTICALS INC. and ALFASIGMA S.p.A. Dated as of July 18, 2019Exclusive License Agreement • July 22nd, 2019 • Innovation Pharmaceuticals Inc. • Pharmaceutical preparations
Contract Type FiledJuly 22nd, 2019 Company IndustryTHIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of July 18, 2019 (the “Effective Date”), by and between INNOVATION PHARMACEUTICALS INC., a Nevada corporation with a principal place of business at 100 Cummings Center, Suit 151B, Beverly, Massachusetts (hereinafter referred to as “IPI”), and ALFASIGMA S.p.A. an Italian corporation with a principal place of business at Via Ragazzi del ’99 n.5, 40133 Bologna (Italy) (hereinafter referred to as “ALFASIGMA”). IPI and ALFASIGMA are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.